RESEARCH AND LICENSE AGREEMENTS (Details Narrative) - USD ($)			1 Months Ended				3 Months Ended			9 Months Ended		47 Months Ended
	Apr. 12, 2024	Apr. 11, 2024	Jul. 31, 2024	Jan. 31, 2022	Jul. 31, 2020	Mar. 31, 2019	Sep. 30, 2024	Apr. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Apr. 30, 2022	Jul. 15, 2024
Research and development expense							$ 123,429		$ 1,441,598	$ 1,242,101	$ 3,898,061
Proceeds from convertible debt			$ 2,000,000.0					$ 1,500,000
Principal amount													$ 1,250,000
License Agreement [Member]
Reimbursement of patent				$ 160,000
License cost							0		12,000	2,000	28,000
Sponsored Research and License Agreement [Member]
License cost							0		0	1,000	22,000
Research and development expense							0		0	0
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member]
Reimbursement of research expenses						$ 693,000				2,900,000
Agreement term payment, description					In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones.
Marketing approval expenses					$ 300,000
Revenue					500,000,000							$ 500,000,000
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]
Upfront license fee					20,000
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]
Upfront license fee					100,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member]
Reimbursement of research expenses												$ 805,000
Agreement term payment, description												In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones.
Marketing approval expenses												$ 500,000
Proceeds from convertible debt												50,000
Patent costs												200,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Licensed Product Sales [Member]
Cumulative sales					5,000,000							5,000,000
Regulatory marketing approval, expenses												500,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]
Milestone payment					50,000							100,000
Shortfall payments												10,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]
Milestone payment					5,000,000							5,000,000
Shortfall payments												50,000
Sponsored Research Agreements And License [Member]
License cost							22,000		18,000	76,000	47,000
Research and development expense							$ 0		$ 101,000	$ 0	$ 657,000
Co Development Agreement [Member]
Funding payment		$ 1,750,000
Exclusivity fee		$ 200,000
Payment for funding	$ 500,000
Agreements under research and development	In return for the Funding Payment we will receive quarterly a 33% payment in the nature of royalties on any Net Sales (as defined with a meaning tantamount to gross profit on net sales) of DuraGraft, capped at double the amount of the Funding Payment cash provided.
Net sales	$ 500,000
Upfront Payment [Member] | License Agreement [Member]
Reimbursement of patent				$ 150,000
Phase 1 Clinical Trial [Member] | License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member]
Milestone payment					50,000							100,000
Phase 2 Clinical Trial [Member] | License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member]
Milestone payment					100,000							200,000
Phase 3 Clinical Trial [Member] | License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member]
Milestone payment					$ 150,000							$ 350,000